18
27 TH JANUARY 2015
| Date post: | 12-Aug-2015 |
| Category: |
Small Business & Entrepreneurship |
| Upload: | caixa-geral-depositos |
| View: | 118 times |
| Download: | 0 times |
2 7 T H J A N U A R Y 2 0 1 5
Team
• Founders:- Rita Ventura - Eva Lourenço- Christopher Maycock- Based on 15 years of academic research
• Business development team:- Pedro Vilarinho, COTEC Portugal- Filipe Aguiar, 73100 – Infraventus
- Founded on November 2013
- Investor: Setenta e Três Mil e Cem, Lda.
ExtremoChem is a start-up company aiming at the development and commercialisation of chemically synthesised novel excipients for the stabilisation of biologics.
Problem/Opportunity
Problem/Opportunity
Active Protein Inactive Protein
Heat and cold
Current solution: cold chain
Certified container
Manufacturers Patient
Distributors
Current solution issues:
temperature excursions
Degradation - loss of efficacy and safety
“Improved thermostability of vaccines is an area of interest for
us”
Senior Director External Scientific Affairs,Merck & Co., USA
Market need
Our solution
Archaeoglobus fulgidus
Hydrothermal vents
• Chemically synthesised analogues of protein stabilising natural compounds with improved stabilisation properties
Our solution
STABILISATION OF BIOPHARMACEUTICALS
Heat and cold
Active Protein Active Protein
Chemical Compound
Value Proposition
Synthesis of new compounds for stabilisation of biopharmaceuticals over a wider range of
temperatures
PHARMACEUTICAL INDUSTRY
Biopharmaceuticals efficacy and safety guaranteed all over the world
• The costs of cold chain failure are estimated to be €5b
• Spin-off of the Imperial College London, 2007
• Excipient mixture derived from seeds and customised to each vaccine - under testing
• Private company based in Cambridge, Massachusetts, founded in 2001
• Liposome encapsulation of vaccine - under clinical trials
Competition
Development status
• Stabilisation of commercially available biopharmaceuticals in the presence of ExtremoChem compounds:
Caninsulin – Porcine insulin, for veterinary use Lantus, Humulin Regular, Actrapid, Insuman Rapid, Insuman
Basal, Humulin NpH, Insulatard - Human Insulin Cervarix and Gardasil – Human papiloma virus vaccine Erythropoietin – Human, recombinant, CHO cells Norditropin SimpleXx – Somatropine, human growth hormone
Development status
• Stabilisation of biopharmaceuticals at room temperature for 10, 15 and 30 days in the presence of ExtremoChem compounds
• Degradation of the proteins at room temperature without added compounds
• The biological activity of the proteins in the presence of our compounds remained the same
IP Protection
• US Provisional Patent submitted during 2013: Hexose derivatives, preparation and uses thereof
• IP Legal advisers: Cooper & Dunham LLP – New York
• PCT application under preparation
• New IP under preparation
Business model
• Co-development for each different indication with relevant pharmaceutical companies
Optimised formulation for the stabilisationof the Active Principle Ingredients (API’s)
• Revenue generated through licensing
Roadmap
2014 2015 2016 2017 2018 2019 ...
IP
Services/Colaborations
Insulins
R&D
2002…
Vaccines
Monoclonal antibodies & Epoetins
EMA
Toxicity Tests
FDA & IPEC
Summary
• ExtremoChem is a tech based start-up
• Commercialisation of new excipients – distribution of biopharmaceuticals without the need of cold chain
• Active and safe biopharmaceuticals all over the world
• Addresses a recognised unmet market need
Thank you for your attention!
Eva Lourenço, [email protected] Ventura, [email protected]
Christopher Maycock, [email protected] Vilarinho, [email protected]
Filipe Aguiar, [email protected]
